References
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235–42.
- Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7:379–91.
- Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013; 381:1817–26.
- Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017; 35:3529–37.
- Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008; 2008:CD003189. doi: 10.1002/14651858.CD003189.pub4
- Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011; 11:404. doi: 10.1186/1471-2407-11-404
- Cornes P, Gascon P, Chan S, Hameed K, Mitchell CR, Field P, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018; 35:1816–29.
- Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018; 26:7–20.
- National Comprehensive Cancer Network. Hematopoietic growth factors (Version 1.2023) [Internet]. 2023 [cited 2023 Feb 1]; Available from:
https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf - Crawford J, Caserta C, Roila F, ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010; 21(Suppl 5):v248–51.
- Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015; 33:3199–212.
- Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012; 20:647–52.
- Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012; 12:297–305.
- Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014; 29:1493–500.
- Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD, et al. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma. 2017; 58:1814–22.
- Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B-cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 2020; 28:571–9.
- Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013; 6:14–7.
- Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res. 2012; 36:548–53.
- Truong J, Lee EK, Trudeau ME, Chan KK. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol. 2016; 27:608–18.
- Ise M, Matsuda K, Shimura A, Masamoto Y, Kurokawa M. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients. Int J Hematol. 2021; 113:823–31.
- Matsuda K, Jo T, Miyauchi M, Toyama K, Nakazaki K, Matsui H, et al. Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: a nation-wide analysis in Japan. J Infect Chemother. 2021; 27:1151–5.
- Posuwan N, Wanlapakorn N, Sa-Nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S, et al. The success of a universal hepatitis B immunization program as part of Thailand's EPI after 22 years' implementation. PLoS One. 2016; 11:e0150499. doi: 10.1371/journal.pone.0150499
- Roschewski M. Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom. Haematologica. 2021; 106:332–4.
- Schmitz N, Frontzek F. CNS prophylaxis in DLBCL: time to say goodbye? Blood. 2022; 139:315–7.
- Kose F, Abali H, Sezer A, Mertsoylu H, Disel U, Ozyilkan O. Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate. Leuk Lymphoma. 2009; 50:282–3.